News from all angles
(MedPage Today) -- The FDA granted accelerated approval to doruxapapogene ralaplasmid and lalikinogene sifuplasmid (Voceryq) to reduce the frequency of surgical papilloma excisions in adults with rec…
Redirecting to MedPage Today in 3 seconds...
Share this story with your network